LEVESQUE SOPHIE

Dr. LEVESQUE SOPHIE


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
AMAurélie Maisonial-Besset
Aurélie Maisonial-Besset
TWTiffany Witkowski
Tiffany Witkowski
MQMercedes Quintana
Mercedes Quintana
SBSophie Besse
Sophie Besse
VGVincent Gaumet
Vincent Gaumet
JCJean-Michel Chezal
Jean-Michel Chezal
The development of 64Cu-based immuno-PET radiotracers requires the use of copper-specific bifunctional chelators (BFCs) that contain functional groups allowing both convenient bioconjugation and stable copper complexes to limit in vivo bioreduction, transmetallation and/or transchelation. The excellent in vivo kinetic inertness of the pentaazamacrocyclic [64Cu]Cu-15-5 complex prompted us to investigate its potential for the 64Cu-labelling of monoclonal antibodies (mAbs), compared with the well-known NODAGA and DOTA chelators. To this end, three NODAGA, DOTA and 15-5-derived BFCs, containing a pendant azadibenzocyclooctyne moiety, were synthesised and a robust methodology was determined to form covalent bonds between them and azide-functionalised trastuzumab, an anti-HER2 mAb, using strain-promoted azide-alkyne cycloaddition. Unlike the DOTA derivative, the NODAGA- and 15-5-mAb conjugates were radiolabelled with 64Cu, obtaining excellent radiochemical yields, under mild conditions. Although all the radioimmunoconjugates showed excellent stability in PBS or mouse serum, [64Cu]Cu-15-5- and [64Cu]Cu-NODAGA-trastuzumab presented higher resistance to transchelation when challenged by EDTA. Finally, the immunoreactive fraction of the radioimmunoconjugates (88–94%) was determined in HER-2 positive BT474 human breast cancer cells, confirming that the bioconjugation and radiolabelling processes implemented had no significant impact on antigen recognition.

28 January 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MCMaria Noelia Chao
Maria Noelia Chao
JCJean-Michel Chezal
Jean-Michel Chezal
EDEric Debiton
Eric Debiton
DCDamien Canitrot
Damien Canitrot
TWTiffany Witkowski
Tiffany Witkowski
AMAurélie Maisonial-Besset
Aurélie Maisonial-Besset
The use of radiolabeled non-natural amino acids can provide high contrast SPECT/PET metabolic imaging of solid tumors. Among them, radiohalogenated tyrosine analogs (i.e., [123I]IMT, [18F]FET, [18F]FDOPA, [123I]8-iodo-L-TIC(OH), etc.) are of particular interest. While radioiodinated derivatives, such as [123I]IMT, are easily available via electrophilic aromatic substitutions, the production of radiofluorinated aryl tyrosine analogs was a long-standing challenge for radiochemists before the development of innovative radiofluorination processes using arylboronate, arylstannane or iodoniums salts as precursors. Surprisingly, despite these methodological advances, no radiofluorinated analogs have been reported for [123I]8-iodo-L-TIC(OH), a very promising radiotracer for SPECT imaging of prostatic tumors. This work describes a convenient synthetic pathway to obtain new radioiodinated and radiofluorinated derivatives of TIC(OH), as well as their non-radiolabeled counterparts. Using organotin compounds as key intermediates, [125I]5-iodo-L-TIC(OH), [125I]6-iodo-L-TIC(OH) and [125I]8-iodo-L-TIC(OH) were efficiently prepared with good radiochemical yield (RCY, 51–78%), high radiochemical purity (RCP, >98%), molar activity (Am, >1.5–2.9 GBq/µmol) and enantiomeric excess (e.e. >99%). The corresponding [18F]fluoro-L-TIC(OH) derivatives were also successfully obtained by radiofluorination of the organotin precursors in the presence of tetrakis(pyridine)copper(II) triflate and nucleophilic [18F]F− with 19–28% RCY d.c., high RCP (>98.9%), Am (20–107 GBq/µmol) and e.e. (>99%).

13 March 2026 in Research Square
Verified
Preprint
Open access
PDF file
MRMaïlys RAGOT
Maïlys RAGOT
PRPauline Reynaud-Orhon
Pauline Reynaud-Orhon
ARAlban Revy
Alban Revy
MBMarie Batisse-Lignier
Marie Batisse-Lignier
VBValentin Brusseau
Valentin Brusseau
MTMarion Tempier
Marion Tempier
Background [ 68 Ga]Ga-NODAGA[40Lys]-Exendin-4 ( 68 Ga-Ex-4) is a new PET radiopharmaceutical targeting GLP-1-R that showed great specificity and sensitivity in the topographic diagnosis of benign insulinoma. We herein report the development of a new method for 68 Ga-Ex-4 radiolabeling in sodium acetate buffer, automated on the miniAllinOne synthesizer. Results Key parameters were reaction volume, due to low amount of peptide, and pH. At a reaction volume of 2.65 and pH 2.9, the reaction yielded 80% of 68 Ga-Ex-4. The use of polysorbate and cooling of the solution allows to decrease the adsorption on the reaction vial (from 29 to 2% of total activity remaining on the vial). 68 Ga-Ex-4 is purified on a HLB cartridge. Final product was obtained within 40 minutes, with a mean radiochemical purity of 97% and a production yield of 67%. Conclusions We have successfully developed a new radiolabeling method for [ 68 Ga]Ga-NODAGA-[40Lys]Exendin-4, automated on a miniAllinOne synthesizer and using sodium acetate buffer, suitable for clinical application.

1 June 2026 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
PDF file
MRMaïlys RAGOT
Maïlys RAGOT
PRPauline Reynaud-Orhon
Pauline Reynaud-Orhon
ARAlban Revy
Alban Revy
MBMarie Batisse-Lignier
Marie Batisse-Lignier
VBValentin Brusseau
Valentin Brusseau
MTMarion Tempier
Marion Tempier
[68Ga]Ga-NODAGA[40Lys]-Exendin-4 (68Ga-Ex-4) is a new PET radiopharmaceutical targeting GLP-1-R that showed great specificity and sensitivity in the topogr